Presentation Information
[EOP3-2]Tislelizumab Plus Chemotherapy versus Triplet Chemotherapy as Neoadjuvant Treatment for Resectable Stage II-III Esophageal Squamous Cell Carcinoma：Preliminary Results of a Randomized Phase II Trial
Lilan Zhao1 (1.Department of Thoracic Surgery, Fuzhou University Affiliated Provincial Hospital, Fuzhou University, Fuzhou, Fujian Province, China, 2.Department of Gastrointestinal and Esophageal Surgery, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian Province, China, 3.Department of Thoracic Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian Province, China)
Password required to view
Comment
To browse or post comments, you must log in.Log in